StreetInsider.com News Articles

Form DEF 14A Incannex Healthcare Inc. For: Dec 17

Wed, 28 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261028/27243882.html

Form DEFA14A Incannex Healthcare Inc.

Wed, 28 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261028/27243872.html

Form ARS Incannex Healthcare Inc. For: Jun 30

Wed, 28 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261028/27243871.html

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26

Thu, 01 Oct 2026 10:54:00 -0400

Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). IXHL's FY26 update moves the IHL-42X story from DReAMzz preparation into active clinical execution, with first-patient dosing underway and the balance sheet providing runway for at least 12 months of planned operations. The study is evaluating approximately 120 patients across nine dose combinations and 14 U.S. sites, with completion expected in mid-2027. In our view, the next several quarters should

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26

Thu, 01 Oct 2026 10:54:00 -0400

Form 10-K Incannex Healthcare Inc. For: Jun 30

Fri, 25 Sep 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260925/27104469.html

Incannex starts patient dosing in sleep apnea trial, holds $70M cash

Wed, 09 Sep 2026 08:02:36 -0400

Incannex Healthcare Inc. (Nasdaq: IXHL) has begun dosing patients in its DReAMzz Phase 2 study of IHL-42X, an oral combination therapy for obstructive sleep apnea, according to a company statement.

The DReAMzz study is a crossover dose-optimization trial being conducted across 13 clinical sites in the United States, each with Institutional Review Board approval. The study is designed to refine the dosing profile of IHL-42X and inform the design of a subsequent Phase 3 registration program. The protocol incorporated feedback from the U.S. Food and Drug Administration.

IHL-42X is a fixed-dose oral combination of dronabinol and acetazolamide. The FDA granted the therapy

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Wed, 09 Sep 2026 08:00:00 -0400

Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea
U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040
Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026

NEW YORK and MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today provides a corporate update reporting the dosing of the first patient

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Wed, 09 Sep 2026 08:00:00 -0400

Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea
U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040
Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026

Incannex doses first patient in IHL-42X sleep apnea study

Tue, 25 Aug 2026 08:46:14 -0400

Incannex Healthcare Inc. (Nasdaq: IXHL) announced that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, its oral fixed-dose combination drug candidate for the treatment of obstructive sleep apnea (OSA).

IHL-42X is a combination of dronabinol and acetazolamide. The DReAMzz study is a crossover trial designed to characterize the dose-response profile of IHL-42X and inform dose selection for a planned Phase 3 program. All 14 clinical trial sites across the United States have received Institutional Review Board approval to conduct the study.

The dosing follows results from the company's earlier Phase 2 RePOSA study, in which

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Tue, 25 Aug 2026 08:46:00 -0400

First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation

NEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, the Company’s oral fixed-dose combination drug candidate for the treatment of obstructive sleep apnea (“OSA”). The milestone builds on the

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Tue, 25 Aug 2026 08:46:00 -0400

Form 8-K Incannex Healthcare Inc. For: Aug 25

Tue, 25 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26970857.html

Form 8-K Incannex Healthcare Inc. For: Aug 25

Tue, 25 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26970857.html

Form SCHEDULE 13G Incannex Healthcare Inc. Filed by: Polar Asset Management Partners Inc.

Fri, 14 Aug 2026 21:54:00 -0400

si-local-file:///var/storage/secattach/20260814/26933354.html

Form SCHEDULE 13G Incannex Healthcare Inc. Filed by: Polar Asset Management Partners Inc.

Fri, 14 Aug 2026 21:54:00 -0400

si-local-file:///var/storage/secattach/20260814/26933354.html

Incannex receives A$5.1M R&D tax refund, totaling A$11.2M in 2026

Tue, 11 Aug 2026 08:01:17 -0400

Incannex Healthcare Inc. (Nasdaq: IXHL) announced it has received a final A$5,102,788.30 refund under the Australian Government's Research and Development Tax Incentive Program, following approval of the company's overseas findings and amendment of its fiscal year 2025 income tax return.

Combined with a previously announced A$6,039,162.43 refund, the clinical-stage biopharmaceutical company has received more than A$11.2 million in total R&D tax incentive proceeds during 2026, according to a press release statement. The funds were received without issuing additional equity or taking on debt.

The refunds relate to eligible Australian research and development activities conducted during the financial year ended June 30, 2025.

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026